

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 3/13/2017  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**von Willebrand Disease (VWF) Sequencing**

ARUP test code 3004379

von Willebrand Disease Specimen                      whole Blood

von Willebrand Disease Interp

Negative

RESULT

No pathogenic variants were detected in the VWF gene.

INTERPRETATION

No pathogenic variants were detected in the VWF gene. This result decreases the likelihood of, but does not exclude, a diagnosis of von willebrand disease. Please refer to the background information included in this report for the methodology and limitations of this test.

RECOMMENDATIONS

Medical management should rely on clinical and phenotypic laboratory findings as well as family history. Consideration may be given to VWF deletion/duplication analysis. Large deletions/duplications in the VWF gene may account for up to 5 percent of causative variants and are most commonly associated with VWD type 1 or 3. If this individual's phenotype is consistent with VWD type 2N, consider F8 gene sequencing (ARUP test code 3004241). If this individual's phenotype is consistent with VWD type 2B, GP1BA gene sequencing should be considered as the phenotype of platelet-type VWD cannot be distinguished from type 2B VWD. Genetic consultation is recommended.

COMMENTS

Likely benign and benign variants, other than the benign c.4414G>C; p.Asp1472His variant, are not reported. Variants in the following region(s) may not be detected by NGS with sufficient confidence in this sample due to technical limitations:

NONE

This result has been reviewed and approved by [REDACTED]

BACKGROUND INFORMATION: von willebrand Disease (VWF) Sequencing

CHARACTERISTICS: Von willebrand disease (VWD) is the most common inherited bleeding disorder and is classified into three major types: type 1, type 2, and type 3. VWF is a large multimeric glycoprotein that plays a critical role in hemostasis. VWF binds factor VIII to protect it from premature degradation, which causes platelet recruitment via the GP1BA receptor and facilitates clot formation. VWD type 1 results from a partial quantitative deficiency of normal plasma von willebrand factor (VWF), type 2 results from a qualitative defect of VWF, and type

**H=High, L=Low, \*=Abnormal, C=Critical**

3 results from severe quantitative VWF deficiency. Type 2 VWD is divided into 4 subtypes: type 2A is characterized by reduced or absent high-molecular weight VWF, type 2B results from gain of function in VWF that increases affinity for platelets or collagen, type 2M is caused by reduced VWF interactions with platelets or collagen, and type 2N results from reduced binding of VWF to FVIII. Individuals with VWD may experience excessive mucocutaneous bleeding including, bruising without trauma, bleeding from gums, prolonged recurrent nosebleeds, menorrhagia, gastrointestinal bleeding, and prolonged bleeding following childbirth, trauma, or surgery.

**EPIDEMIOLOGY:** Prevalence of symptomatic VWD is estimated at 1 in 10,000. Of individuals with VWD, approximately 30 percent have type 1, 60 percent have type 2, and less than 10 percent have type 3.

**CAUSE:** Pathogenic germline variants in the VWF gene.

**INHERITANCE:** Autosomal dominant: types 1, 2B, 2M, and most cases of type 2A. Autosomal recessive: types 2N, 3, and 20 percent of type 2A cases.

**PENETRANCE:** For autosomal dominant types 1, 2A, 2B, and 2M, penetrance is incomplete when VWF:Ag and VWF:RCO levels are between 30 and 50 IU/dL. Full penetrance is expected when VWF:Ag and VWF:RCO levels are less than 30 IU/dL. Heterozygous carriers of type 3 or type 2N are often asymptomatic; however, some individuals may show mild bleeding symptoms.

**CLINICAL SENSITIVITY:** 80 percent for VWD type 1 and 90 percent for VWD types 2 and 3.

**GENE TESTED:** VWF (NM\_000552)  
Exons 26 and 34 are not covered by sequencing, and deletion/duplication analysis is not available for this gene.

**METHODOLOGY:** Capture of all coding exons and exon-intron junctions of the VWF gene, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and confirm reported variants. Human genome build 19 (Hg 19) was used for data analysis.

**ANALYTICAL SENSITIVITY/SPECIFICITY:** The analytical sensitivity of this test is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions from 1-10 base pairs in size. Variants greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced.

**LIMITATIONS:** A negative result does not exclude a diagnosis of von Willebrand disease. This test only detects variants within the coding regions and intron-exon boundaries of the VWF gene. Regulatory region variants and deep intronic variants will not be identified. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions. This assay may not detect low-level mosaic or somatic variants associated with disease. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed. Variants interpreted as pathogenic, likely pathogenic, and of uncertain significance will be reported, as will the benign variant VWF c.4414G>C; p.Asp1472His; other likely benign or benign variants are not reported.

The following regions are not sequenced due to technical limitations of the assay: VWF (NM\_000552) exon(s) 26, 34

This test was developed and its performance characteristics

**H=High, L=Low, \*=Abnormal, C=Critical**

determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
von Willebrand Disease Specimen	23-122-101847	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
von Willebrand Disease Interp	23-122-101847	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at: